Medesis Pharma S.A.: management transactions · France · AMF

About Medesis Pharma S.A.

MEDESIS PHARMA S.A. is a French biopharmaceutical company listed on Euronext Growth Paris under ticker ALMDP (ISIN: FR0010844464). Founded in April 2003 by Jean-Claude Maurel, the company was established to consolidate and further develop intellectual property arising from earlier research on lipid components and their therapeutic potential. Headquartered near Montpellier, Medesis Pharma is positioned as a clinical-stage biotech focused on the design of drug candidates and innovative oral delivery systems for active pharmaceutical ingredients. The company’s business model is anchored in its proprietary AONYS® platform, a microemulsion/nanomicelle technology designed to deliver water-soluble molecules through the buccal route. The purpose of this platform is to improve bioavailability, simplify administration, and broaden the therapeutic scope of existing molecules. AONYS® underpins most of Medesis Pharma’s research and development pipeline. The company is therefore active across several therapeutic domains: neurodegenerative diseases, infectious and inflammatory diseases, certain cancers, radioprotection, and decorporation therapies for radionuclide exposure. Its flagship program is NanoLithium®, aimed at treating Alzheimer’s disease and also studied in Huntington’s disease. Recent corporate communications indicate meaningful clinical progress, including the completion of a clinical study in 2024 and encouraging results from the first phase of a trial. Medesis Pharma is also developing NanoManganese® for radioprotection and to enhance the efficacy and safety of radiotherapy in oncology, alongside programs intended for populations contaminated or irradiated after a nuclear accident. Historically, the company has also pursued COVID-19-related candidates and collaborative oncology programs. From a scientific and industrial standpoint, Medesis Pharma stands out for its highly targeted approach to diseases with substantial unmet medical need. The company emphasizes its patent portfolio, scientific publications, and a development strategy built around preclinical validation followed by clinical proof of concept. Its geographic footprint is mainly French, with a strong base near Montpellier, but its scientific and regulatory communications are international in scope, including presentations at specialized conferences and multi-site clinical development. As a niche biotech with high scientific ambition, Medesis Pharma remains exposed to the execution risks typical of drug development, yet it occupies a distinctive position in oral nanodelivery and next-generation pharmaceutical innovation.